Indexed with PubMed and Science Citation Index (E) 
Users online: 4279 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article
   To the Editor,

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal


Year : 1996  |  Volume : 62  |  Issue : 6  |  Page : 411-412

Fixed duration MDT in leprosy

Correspondence Address:
Mohan Gharpuray

Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 20948152

Rights and PermissionsRights and Permissions

How to cite this article:
Gharpuray M, Kulkarni V. Fixed duration MDT in leprosy. Indian J Dermatol Venereol Leprol 1996;62:411-2

How to cite this URL:
Gharpuray M, Kulkarni V. Fixed duration MDT in leprosy. Indian J Dermatol Venereol Leprol [serial online] 1996 [cited 2019 Oct 22];62:411-2. Available from: http://www.ijdvl.com/text.asp?1996/62/6/411/4489

  To the Editor, Top

This letter is in reference to the article by Paramjit Kaur and Gurmohan Singh on 'Fixed duration MDT in leprosy and clinical cure' (IJDVL 1996;62:33-5).

We think practically all will agree that it is advisable to achieve clinical cure. We however do not agree that the patients covered by the national programme should have different treatment than patients under care of dermatologists. This is especially so because of the ever increasing incidence of relapses after FDT.[1]

We are giving herewith the opinion of practising dermatologists from all over Maharashtra (except Mumbai) who were asked questions related to FDT. Out of the 142 dermatologists contacted 92 responded.

  1. 1. For monolesional paucibacillary cases 88.1% do not stop treatment at the end of 6 months as suggested by WHO.

  2. 2. For paucibacillary cases with multiple lesions 81.5% do not stop treatment at the end of 12 months as suggested by WHO.

  3. 3. For multibacillary cases 93.5% do not stop treatment at the end of 24 months.

Thus overwhelming number of dermatologists give importance to the clinical activity and do not follow the FDT schedules as suggested by WHO.

We would like to add from our experience that with relative affluence in our state, not so costly MDT and availability of qualified dermatologists in all district places and most of the taluka places, dermatologists are treating more leprosy patients in their clinics than the patients being treated at the government hospitals.

One of us has tried to give a critique of the WHO schedules and suggested that the urgency of reducing the duration of therapy is unnecessary and may prove counterproductive in the long run.[2]

  References Top

1.Jamet P, Ji B, Marchoux Chemotherapy Study Group. Relapse after long term follow up of multibacillary patients treated by WHO multi drug regimen. Int J Lepr 1995;63:195-201.  Back to cited text no. 1    
2.Kulkarni V. Will extensive use of WHO recommended MDT regimens control leprosy? some reflections. ILA Forum 1995;2:8-13.  Back to cited text no. 2    


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow